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Background: Coumarin and its derivatives are biologically very active. It was found that the enhanced activities
are dependent on the coumarin nucleus. Biological significance of these compounds include anti-bacterial,
anti-thrombotic and vasodilatory, anti-mutagenic, lipoxygenase and cyclooxygenase inhibition, scavenging of
reactive oxygen species, and anti-tumourigenic. Our interest in medicinal chemistry of dicoumarol compounds have
been developed by keeping in view the importance of coumarins along with its derivatives in medicinal chemistry.
All the synthesized compounds were fully characterized by spectroscopic and analytical techniques and were
screened for antimicrobial and U2OS bone cancer activities.
Results: 4-hydroxycoumarin was derivatized by condensing with different aldehydes yielding the dicoumarol and
translactonized products. Elemental analyses, ESI(+,−) MS, 1H and 13C{1H}-NMR, infrared spectroscopy and
conductance studies were used to characterize the synthesized compounds which revealed the dicoumarol and
dichromone structures for the compounds. The compounds were screened against U2OS cancerous cells and
pathogenic micro organisms. The compounds with intermolecular H-bonding were found more active revealing a
possible relationship among hydrogen bonding, cytotoxicity and antimicrobial activities.
Conclusion: Coumarin based drugs can be designed for the possible treatment of U2OS leukemia.
Keywords: Dicoumarols, Translactonized products, Antimicrobial activity, U2OS anticancer activityBackground
Medicinal application of coumarin derivatives
Coumarins are naturally occurring organic compounds
[1,2] which belong to benzo-α-pyrones group of com-
pounds. Coumarin derivatives are widely used in the field
of medicines and drugs for many years [2-7] as for ex-
ample coumarin and its derivatives exhibited pronounced
anticancer and antimicrobial activities as revealed from lit-
erature. Coumarin derivatives have been applied for treat-
ment of various cancerous diseases including malignant* Correspondence: sadia_rehman571@yahoo.com; ikram.chemistry@suit.edu.
pk; srachem@yahoo.com
†Equal contributors
1Institute of Chemical Sciences, University of Peshawar 25120, Peshawar, Pakistan
2Department of Chemistry, Sarhad University of Science and Information
Technology, Peshawar, Pakistan
Full list of author information is available at the end of the article
© 2013 Rehman et al.; licensee Chemistry Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediummelanoma, leukemia, renal cell carcinoma, prostate and
breast cancer [2-8]. When those compounds were applied
in combination with radiotherapy and surgery as a chemo-
therapeutic agent provided best results, treating not only
the cancer but also decreased the side effects of radio
therapy [8].
Initially, the melanoma diagnosis involved just the sur-
gical removal of primary lesion with the high risk of re-
currence after five years. However, the problem has been
minimized by the use of 4-hydroxy coumarin along with
warfarin to maintain therapy and to inhibit the tumor
spread [9]. In case of leukemia, prostate and breast can-
cer, cyclin D1 is released in an amount more than a nor-
mal levels and coumarin derivatives have also been
found very effective antiproliferative agents by regulating
the release of cyclin D1 [10-19].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Drugs used for treating sarcoma.
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There are different types of sarcomas including the syn-
ovial sarcoma, Ewing's sarcoma and osteosarcoma which
are more often found in young adults and neoplasias such
as leiomyosarcoma or liposarcoma are found in humans of
more than 55 years age [20-22]. Synovial sarcoma is being
treated using doxorubicin and ifosfamide [22]. The doxo-
rubicin has been found to cause neutropenia, alopecia,
dispigmentation, and reactivation of Hepatitis B, cardiomy-
opathy or even death. Therefore due to its very toxic na-
ture it had been named as “Red Devil” [23-26] (Figure 1).
Similarly ifosfamide causes encephalopathy (brain dys-
function), a very serious drawback of the drug. Encepha-
lopathy is actually caused by the production of toxic side
products like acetaldehyde and chloral hydrate [25,26].
Coumarin and its derivatives are biologically very ac-
tive. It was found that the enhanced activities are
dependent on the coumarin nucleus [25,26]. Biological sig-
nificance of these compounds include anti-bacterial [27],
anti-thrombotic and vasodilatory [28], anti-mutagenic [29],
lipoxygenase and cyclooxygenase inhibition [30,31], scaven-





Scheme 1 Synthesis of coumarine derivatives.[32,33]. The fact that such compounds have medicinal
applications, prompted many researchers to work in this
field and several recent reviews summarize advances in this
field [34-38].
Our interest in medicinal chemistry of dicoumarol
compounds have been developed by keeping in view the
importance of coumarins along with its derivatives in
medicinal chemistry. We envisioned the synthesis of di-
coumarol compounds by reacting 4-hydroxy coumarin
with various aldehydes (Scheme 1). All the synthesized
compounds were fully characterized by spectroscopic
and analytical techniques and were screened for anti-
microbial and U2OS bone cancer activities.
Result and discussion
Spectral studies
4-hydroxy coumarin was condensed with different alde-
hydes in ethanol under reflux. All the compounds were
characterized using different techniques including 1H, 13C
{1H}-NMR, high resolution ESI-MS, elemental analysis, and
infrared spectroscopic techniques. General reaction is given










Figure 2 Atoms numbering used for NMR signals.
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aldehyde center produced dicoumarol compounds ex-
cept salicyldehyde and 2- hydroxynaphthaldehyde, the
ortho hydroxy substituted aldehydes, yielded a mixture
of translactonised and dicoumarol products. 1H-NMR
revealed that all the dicoumarol compounds followed
the Michael addition reaction. Condensation of benz-
aldehyde, 4-nitrobenzaldehyde, 4-chlorobenzaldehyde,
3-pyridinecarboxaldehyde, 3-indolecarboxaldehyde, 4-me
thoxybenzaldehyde, N,N-dimethyl-4-benzaldehyde and va-
niline produced dicoumarol compounds which were unam-
biguously characterized and confirmed using spectroscopic
and analytical techniques. Elemental analyses established
the composition which was further confirmed by high reso-
lution ESI(+,−) MS spectral analysis. The percent abun-
dance coincides with the respective molecular ion peaks.
1H and 13C{1H}-NMR were carried out for all the
compounds using DMSO-d6. The NMR assignment for
dicoumarols is based on Figure 2. The enolic protons
were found to be involved in the formation of hydrogen
bonding. A singlet at 10-12 ppm in different dicoumarol
compounds were assigned to those enolic protons because





Scheme 2 Tautomerism in coumarin structure.A singlet at 6 ppm was assigned to the methylene group
of the aldehydes which connects both the moieties. This
singlet can also be observed at about 9.8-12 ppm because
of the possible tautomerism as may be seen in Scheme 2.
Rest of the NMR spectra clearly coincides with their re-
spective peaks for each proton.
The solid state ATR spectra were recorded for all the
compounds in 400-4000 cm−1 spectral region. Since the
IR spectra of all the compounds were quite similar
therefore discussion is confined to the important vibra-
tions only. The carbonyl stretching frequency varies
from 1600-1730 cm−1 which may be due to the inter-
action of carbonyl group with the hydroxyl group to
produce strong hydrogen bonding. Earlier studies re-
vealed that carbonyl group involved in hydrogen bond-
ing vibrates at lower frequency. The hydrogen bonding
may either be intermolecular or intramolecular as shown
in Scheme 3.
Compound 5, 9 and 10 have carbonyl stretching fre-
quencies at 1700-1730 cm−1 whereas 2, 4, 6 and 7 were
observed to be vibrating around 1645-1680 cm−1, a di-
coumarol structure (structure A) was assigned as shown
in Scheme 4.
Compounds 1, 3, and 8 were observed to have car-
bonyl stretching frequency at 1600-1630 cm−1 which is
around 30-60 cm−1 lower than the stretching frequency
for 2, 4, 6 and 7, a dichromone structure (structure B)
was assigned as given in Scheme 4. Rest of the IR
spectrum was assigned to their respective peaks [22].
Compound 5 and 10 were found to be a mixture of two
products, a) dicoumarol compound and b) translactonized
product (Scheme 1).
A weak band in the range of 1090-1120 cm−1 was
assigned to the stretching frequency of C-O of lactone
ring. Hydroxyl group is involved in hydrogen bond for-
mation therefore the band is weakly observed. There is
also a strong vibration around 1040 cm−1 in both the
compounds which is assigned to the complementary
band for the ketone carbonyl carbon.
It was found that there is a type of competition between
the two products which dominates the formation of
translactonised product. The two products were separated
by coloumn chromatography using alumina as stationary























Scheme 3 Hydrogen bonding in dicoumarol compounds.
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dicoumarol derivatives are collected by using methanol
containing triethylamine (70% : 30%). It was found that
85-94% product is translactonised whereas the dicoumarol
compound varies between 5-12% in abundance. 1H and
13C{1H}-NMR spectroscopy was performed to confirm the
formation of those products. Figure 3 was used for assign-
ment of resonances in 11 to their respective protons
whereas Figure 4 was used for compound 12. 1H-NMR
for 11 show a singlet around 12.56 ppm which was
assigned to the proton of phenolic OH group. Similarly, a
singlet around 10.79 ppm was tentatively assigned to the
H(10), a proton of methylene group of the coumarine ring.
The protons at this position in compound 12 were ob-
served around 10.70 ppm. The rest of the resonances
for both compounds were assigned to the protons of aro-
matic ring system. The compounds were confirmed to be
translactonized by studying the 13C{1H}-NMR which show
peaks around 192 ppm, assigned to C=O group of ketone.
Similarly the lactone C=O was assigned to the peak ap-
pearing around 181 ppm. These two peaks are identical in
both the compounds. Rest of the spectrum was assigned to
their respective carbon atoms. Infrared spectrum reveals
absorption bands around 1714 cm−1 which was assigned to
the C=O stretching frequency of the ketone. A weak band







Dicoumarol structure  (A)
Scheme 4 Dicoumarol and dicoumrone structures.stretching frequency of C-O of lactone ring. The OH group
is involved in H-bond formation and the band is weakly ob-
served. There is also a strong vibration around 1040 cm−1
in both the compounds, which is assigned to the comple-
mentary band for the ketone C=O carbon.Crystal structure of 11
Compound 11 was crystalized out from MeOH solution
of the product. The ORTEP plot of 11 is shown in
Figure 3 and the crystal data in Table 1. A complete asym-
metry was observed around the carbonyl carbon C(12a).
This asymmetry can be seen by comparing the dihedral
angle between the planes C(2a)-O(3a)-C(4a)-C(5a)-C(6a)-
C(7a)-C(8a)-C(9a)-C(10a)-C(11a) and C(13a)-C(14a)-
C(15a)-C(16a)-C(17 a)-C(18a) which was found to be
59.24o. The crystal packing diagram show that intermo-
lecular hydrogen bonding between O(1a) and H(18) of
the neighboring ring of 2.537Ao bond length is involved.
Apart from it weak Van der Waals interactions may be
seen between the rings C(2a)-O(3a)-C(4a)-C(5a)-C(6a)-
C(7a)-C(8a)-C(9a)-C(10a)-C(11a) of two neighboring
molecules. These interactions hold the rings by distance
of 3.385Ao through π-π stacking. There is strong intra-
molecular hydrogen bonding of 1.823Ao length between





Figure 3 Molecular Structure of 11 with labeled H-atoms. (Numbering was used for NMR assignment of 11).
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All the synthesized compounds were studied In vitro for
their antimicrobial activities and the results are shown
in Table 2. The table depicts that all the tested com-
pounds are active against Bacillus atrophaeus, except
compounds 5, 6, and 8 which showed moderate activities.
Compounds 1, 3, 7 and 10 are more active against Bacil-
lus subtilis, while all other compounds were moderately
active. All the compounds were inactive against Klebsiella
pneumonia and Salmonella typhus except some dicou-
marols as may be seen in Table 2. Similarly moderate
activities were observed against Pseudomonas aeruginosa
and Escherichia coli. Interesting results were observed for
compound 5 and 10 against Candida albican and
Agrobacterium tumefaciens which were more active than
the standard drug. Compounds 1, 7, 8 and 9 were also
more active than the standard but their activities are less
pronounced than compound 5 against Candida albican.
Compound 6 also showed comparable activity against
Agrobacterium tumefaciens. Except compound 2, all the
compounds were active against Agrobacterium tumefaciens.
Compound 7 showed moderate activity whereas rest of the
other compounds were found inactive against Erwinia
carotovora.Figure 4 Labelled diagram of 12 for NMR assignment.Cytotoxic Activity
All the synthesized coumarin derivatives were subse-
quently studied for their cytotoxicity against U2OS osteo-
blast cancerous cells. The results are shown in Figure 5
which reveals that all the compounds have significant
LD50 values except 3 which never dropped beyond 65%
for its cytotoxicity. The compound 7 showed moderate
LD50 value at 1.5 μM concentration while rest of the com-
pounds exhibited LD50 at 2 μM concentration. Compound
10 showed LD50 value at very lower concentration unlike
the others. The good results of compound 10 may be at-
tributed to the presence of salicylic ring, an active part of
majority of drugs, and also its activity may be due to the
presence of hydroxyl group. Therefore it can be hypothe-
sized from these observations that hydroxyl group and its
orientation in a compound plays vital role in determining
the cytotoxic activities of the active compounds.
Similarly the translactonized compounds 11 and 12 were
also evaluated for their effectiveness against osteoblast can-
cerous cells. It can be revealed that both the compounds
exhibited a well-behaved cytotoxicity curve with an LD50
value of 1.2 μM for 11 and 2 μM for 12; Figure 1. The
lower LD50 value for 11 as compared to 12 can be under-
stood by looking into the structural features and solubil-
ities. There is not much difference between the two
compounds except the addition of extra hydrophobic
phenyl ring. The added phenyl ring is making compound
12 harder to be soluble in coordinating low polarity sol-
vents as compared to highly polar and strong coordinating
solvents (like DMSO). Therefore it can be revealed that in-
creasing fused ring system lowers the activity many folds
by lowering the hydrophilic interaction.
Previously columbamine (COL), zoledronic acid, epi-
gallocatechin gallate (EGCG) and an interleukin (IL)-1
receptor antagonist, huperine and monoclonal antibody
were reported for their possible therapeutic application
against U2OS sarcomyses [39-41]. Recently, Bao et al. [42]
reported columbamine to be involved in effective

















Crystal size/mm3 0.371 × 0.059 × 0.039
2Θ range for data collection 6.34 to 53.9°
Index ranges −31 ≤ h ≤ 24, −2 ≤ k ≤ 4, −28 ≤ l ≤ 27
Reflections collected 6018
Independent reflections 2356 [R(int) = 0.093]
Data/restraints/parameters 2356/1/363
Goodness-of-fit on F2 1.040
Final R indexes [I>=2σ (I)] R1 = 0.0874, wR2 = 0.1780
Final R indexes [all data] R1 = 0.1558, wR2 = 0.2210
Largest diff. peak/hole / e Å−3 0.38/−0.26
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http://journal.chemistrycentral.com/content/7/1/68inhibition of expression of MMP2 expressions at very low
concentrations. But here the reported dicoumarol com-
pounds like 3 and 10, translactonised products like 11 and
12 demonstrated effective inhibition of U2OS sarcoma as
compared to the COL. The same mechanistic approach
for the effectiveness of the coumarin based tumoricidal
agents can be assigned which involves the suppression
of neovascularization, adhesion, migration, and invasion.
The cytotoxic concentrations are very low as compared
to the reported drugs therefore U2OS tumoricidal agents




All chemicals, buffers and solvents used were of analyt-
ical grade. Benzaldehyde, 4-nitrobenzaldehyde, 4-chloro
benzaldehyde, and N,N-dimethyl-4-benzaldehyde were
obtained from Fluka whereas 3-pyridinecarboxaldehyde, 3-
indolecarboxaldehyde, 4-methoxybenzaldehyde, vaniline,2-hydroxynaphthaldehyde and salicyldehyde were obtained
from Sigma Aldrich and were used as such without further
purification. Solvents were obtained from local suppliers of
Sigma Aldrich, Merck and Fluka and were distilled at least
twice before use. Unless otherwise stated, all reactions
were carried out under dinitrogen atmosphere.
Instrumentation
Elemental analyses were carried out on Varian Elementar
II. IR spectra were recorded using Shimadzo FTIR Spec-
trophotometer Prestige-21. 1H-NMR were measured with
Bruker DPX 400 MHz (400.23 MHz) whereas, 13C{1H}
NMR were recorded on Bruker AV 400 MHz (150.9 MHz)
spectrometers in , (CD3)2OS at room temperature. Chem-
ical shifts are reported in ppm and standardized by observ-
ing signals for residual protons. Molar conductance of the
solutions of the metal complexes was determined with a
conductivity meter type HI-8333. All measurements were
carried out at room temperature with freshly prepared so-
lutions. Mass spectra were recorded on a LCT Orthogonal
Acceleration TOF Electrospray mass spectrometer.
Crystal Structure Determination
Single crystal analyses were carried out using suitable
single crystals for X-ray structural analyses of 11 was
mounted on a glass fiber, and the respective data were col-
lected on oxford diffractometer (graphite-monochromated
Mo Kα radiation, λ = 0.71073 Å) at 108(2) K. The struc-
tures were solved with the olex2.solve [43] structure solu-
tion program using Charge Flipping and refined with the
olex2.refine [Bourhis LJ, Dolomanov OV, Gildea RJ, How-
ard JAK, Puschmann H: Olex2.refin. 2011. in preparation]
refinement package using Gauss-Newton minimization.
Crystallographic details are given in the Additional file 1
CCDC 888786 (1) data can be obtained free of charge
from the Cambridge Crystallographic Data Centre via
www.ccdc.cam.ac.uk/data_request/cif.
Antimicrobial activity
About 2.8 g/L nutrient agar and nutrient broth were pre-
pared in deionized water and kept in autoclave set at 1.5
Pounds pressure for about 15 min. Under inert atmos-
phere the nutrient agar media were poured aseptically into
sterilized petri dishes in laminar flow. The petri dishes
were kept for about 24 hrs. at 37°C in inverted position.
Bacterial cultures were adjusted to 0.5 McFarland tur-
bidity standards and Candida albican was adjusted to
108 cfu/ml. Sterile filter paper of diameter 6 mm was used
for bacterial strains whereas its thickness ranged upto
13 mm for fungal strains. These filter papers were in
the form of discs and were seeded with 0.5 McFarland
and 106 cfu/ml cultures of bacteria and fungi respectively.
Solutions (0.5 mM) of the synthesized compounds were
applied to the prepared discs and incubated for 18 hr at

















(mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm) (mm)
1 25 22 — — 20 14 16 22 22 15
2 12 09 09 06 09 — 16 12 10 10
3 26 22 — — 16 — 09 15 20 —
4 17 17 — — 18 12 __ 12 16 11
5 15 12 — 11 15 10 13 30 20 —
6 13 15 — — 18 — 13 19 27 13
7 21 22 — 12 18 12 11 20 24 17
8 16 20 11 — 20 09 15 20 20 —
9 21 21 12 10 19 19 09 21 20 15
10 22 25 — — 15 12 12 — 28 11
11 23 22 15 12 21 21 10 21 20 15
12 15 15 — 10 10 15 14 30 21 —
Standard 25 26 29 42 36 38 34 16 15 26
Gram positive bacteria: Bacillus atrophaeus, Bacillus subtilis, Staphylococcus aureus, standard used was erythromycin in 6 μM.
Gram negative bacteria: Klebsiella pneumoniae, Salmonella typhus, Pseudomonas aeruginosa, Escherichia coli, Agrobacterium tumefaciens, Erwinia carotovora, standard used was ciprofloxacin in 6 μM.














Figure 5 A) Cytotoxicity curve for the coumarin derivatives B) cytotoxicity curve for compound 11.
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were carried out [21].
Cytotoxic activity
The human osteosarcoma cell line U2OS was used for test-
ing the tumoricidal activities of all coumarin compounds.
The cells were cultured in DMEM+ GlutaMAXTM−1 with
added 1% penicillin and streptomycin and 10% heat-
inactivated fetal bovine serum. For adherent cells, trypsin-
EDTA was used for detachment. The cells were washed in
Dulbecco’s phosphate buffered saline (DPBS), harvested by
centrifugation (1000 rpm, 5 min), and resuspended in
DMEM. The cells were seeded into 96-well plates at a
density of 5 × 103 cells / well, and incubated at 37°C in 5%
CO2 atmosphere for 24 hours before being treated with
the compounds. The compounds were initially dissolved at
a stock concentration of 10 mM in DMSO and added to
wells to a final concentration between 5.0 and 200 μM.
The plates were then incubated at 37°C for a further24 hours for treatment. Alamar blue (Invitrogen) was used
to test the viability of the cells (10 μl per well). Plates in
triplicate were incubated for 4 hours at 37°C protected
from direct light, then read at 590 nm using an excitation
wavelength of 544 nm in a fluorescence plate reader (Spec-
tra Max Gemini). Wells containing medium and distilled
water-only served as blank controls, while the viability of
the treated cells was taken as a percentage compared to
wells with untreated cells. The LD50 value of each com-
pound was estimated by fitting the correlation between cell
viability and compound concentration.
Synthesis of dicoumarol ligands
The dicoumarol ligands were synthesized by the re-
ported procedure with slight modifications [22], 25 mmol
of the aldehydes were added to the 50 mmol stirred
ethanolic solution of 4-hydroxycoumarin and the mix-
ture was refluxed for 3 hr at 120°C. After cooling the re-
action mixture, solid white powder of the ligands were
Rehman et al. Chemistry Central Journal 2013, 7:68 Page 9 of 12
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ethanolic n-hexane solution. The product was purified
by dissolving in methanolic solution containing small
volume of triethylamine. The process repeated two times
to get pure recrystalised dicoumarol ligand. The forma-
tion of dicoumarol ligand may be seen in Scheme 1.
3.6.1 3,3'-(phenylmethanediyl)bis(4-hydroxy-2H-chromen-2-
one) (1)
IR: 3317(s), 3244(s), 3010(s), 1600(s), 1537(w), 1485(w),
1463(w), 1446(w), 1379(w), 1327(s), 1247(s), 1188(w), 1126
(w), 1072(w), 1010(w), 831(s), 761(s), 711(s), 665(s) cm−1,
1H-NMR (400.23 MHz, (CD3)2OS, 303 k): δ = 6.31 (s, 1H,
C12), 7.05-7.95 (m, H-aromatic), 10.01 (s, 2H, OH); 13C
{1H}-NMR (150.9 MHz, (CD3)2OS,) (δ, ppm): 35.88 (C12);
102.66-131.74, (Carom); 152.44 (C4,C18), 165.63 (C2,C14),
Elemental Analysis (C25H16O6), Calc. C: 72.81%, H: 3.91%,





IR: 3500(bd), 3061(w), 2910(s), 2131(bd), 1681(s), 1610(s),
1531(s), 1456(s), 1408(s), 1348(w), 1276(s), 1253(w), 1178
(s), 1105(s), 1049(s), 1004(s), 941(s), 900(w), 848(w), 806
(s), 748(s), 677(s), 626(s), 605(s), 551(s) cm−1, 1H-NMR
(400.23 MHz, (CD3)2OS, 303 k): δ = 6.40 (s, 1H, C12),
7.25-8.71 (m, H-aromatic), 10.13 (s, 1H, -OH), 13C{1H}-
NMR (150.9 MHz, (CD3)2OS,) (δ, ppm): 101.71 (CH,
C12), 115.74-144.62(Carom), 152.64 (C4,C18), 164.02
(C2,C14), Elemental Analysis (C24H15NO6), Calc. C:
69.73%, H: 3.66%, N: 3.39%, Exp. C: 66.80%, H: 3.10%, N:




IR: 3350(bd), 2980(w), 2740(bd), 1614(s), 1516(s), 1470(s),
1338(s), 1294(s), 1242(s), 1193(s), 1116(s), 952(s), 831(s),
756(s), 734(s), 638(s) cm−1, 1H-NMR (400.23 MHz, (CD3)
2OS, 303 k): δ = 5.60 (s, 1H, C12), 7.19-8.30 (m, H-
aromatic), 9.93 (s, 1H, NH), 12.16 (s, 1H, OH), 13C{1H}-
NMR (150.9 MHz, (CD3)2OS,) (δ, ppm): 90.85 (CH, C12),
112.34-138.73 (C, C aromatic), 153.53 (C4,C18), 162.03
(indole), 165.63 (CH, indole), 185.19 (C2,C14), Elemental
Analysis (C27H17NO68), Calc. C: 71.84%, H: 3.80%, N:
3.10%, Exp. C: 66.80%, H: 3.31%, N: 3.09%, EI-MS: m/z




IR: 2800(w), 1650(s), 1602(s), 1558(s), 1506(s), 1448(w),
1352(s), 1305(s), 1257(s), 1176(s), 1093(s), 1053(s), 960
(s), 904(s), 767(s), 673(s) cm−1, 1H-NMR (400.23 MHz,
(CD3)2OS, 303 k): δ = 3.72 (s, 3H, OCH3); 6.23 (s, 1H,C12), 6.75-7.85 (m, H-aromatic), 10.01 (s, 1H, OH); 13C
{1H}-NMR (150.9 MHz, (CD3)2OS,) (δ, ppm): 54.87
(CH3, -OCH3), 103.78 (CH, C12), 112.12-131.33 (C, C-
aromatic), 152.18 (C4,C18), 169.70 (C2,C14), Elemental
Analysis (C26H18O7), Calc. C: 70.58%, H: 4.10%, Exp. C:





IR: 3066(w), 1705(s), 1629(s), 1566(s), 1487(s), 1394(s),
1286(s), 1249(s), 1205(s), 1149(s), 1091(s), 1004(w), 927
(s), 873(s), 817(s), 744(s), 677(s), 617(s) cm−1, 1H-NMR
(400.23 MHz, DMSO-d6, 303 k): δ = 5.60 (s, 1H, C12),
6.94-8.64 (m, H-aromatic), 10.70 14 (s, 1H, Ar-OH),
ppm, 13C{1H}-NMR (150.9 MHz, DMSO-d6, 303 k): δ =
192 (C2,C14)ppm, 159 (Ar-OH), 158 (C4,C18), 138.8-
123 (Aromatic carbons), 98.23 (CH, C12), ppm, Elemen-
tal Analysis (C29H20O7), Calc. C: 72.49%, H: 4.20%, Exp.
C: 72.60%, H: 4.12, EI-MS: m/z (%) 477.0974 (5%)
[C29H17O7-H






IR: 3200(bd), 2750(w), 1645(s), 1600(s), 1523(s), 1454
(s), 1342(s), 1309(s), 1265(s), 1184(s), 1099(s), 1029(s), 960
(s), 912(s), 813(s), 792(s), 675(s) cm−1, 1H-NMR
(400.23 MHz, (CD3)2OS, 303 k): δ = 6.34 (s, 1H, C12),
7.23-8.54 (m, H-aromatic), 10.14 (s, 1H, Ar-OH), 13C{1H}-
NMR (150.9 MHz, (CD3)2OS, 303 k), δ = 97.61 (CH, C12),
115.22-147 (C, C aromatic), 152., 27 (C4,C18), 164.49 (C2,
C14)ppm, Elemental Analysis (C25H15NO8), Calc. C:
65.65%, H: 3.31%, N: 3.06%, Exp. C: 66.80%, H: 3.10%, N:




IR: 2740(w), 1662(s), 1602(s), 1558(s), 1489(s), 1454(w),
1350(s), 1307(s), 1219(w), 1093(s), 1016(s), 954(w), 906
(s), 819(s), 763(s), 673(s) cm−1, 1H-NMR (400.23 MHz,
(CD3)2OS, 303 k): δ = 5.61 (s, 1H, C12), 6.28-7.93
(m, H-aromatic), 13C{1H}-NMR (150.9 MHz, (CD3)2OS,
303 k), δ = 103.50 (CH, C12), 115.97-140.26 (C, aromatic),
152.21 (C4,C18), 164.22 (C2,C14)ppm, Elemental Analysis
(C25H15ClO6), Calc. C: 67.20%, H: 3.38%, Exp. C: 67.80%, H:




IR: 3356(bd), 2700(w), 2600(bd), 1614(s), 1598(s), 1548(s),
1516(w), 1342(s), 1323(s), 1292(s), 1273(s), 1242(s), 1188
(s), 952(s), 935(s), 829(s), 756(s), 704(s), 682(s), 667((s),
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δ = 2.50 (s, 6H, NCH3), 5.60 (s, 1H, C12), 7.32-7.96
(m, H-aromatic), 13C{1H}-NMR (150.9 MHz, (CD3)2OS,
303 k), δ = 56.23 (CH3, NCH3), 91.05(CH, C12), 115.82-
153.72 (C, C aromatic), 161.93 (C4,C18), 165.36 (C2,C14)
ppm, Elemental Analysis (C27H21NO6), Calc. C: 71.20%,
H: 4.65%, N: 3.08%, Exp. C: 71.83%, H: 4.60%, N: 3.98%,




IR analysis: 3063 (m), 1703 (s), 1622 (m), 1599 (m), 1567
(s), 1512 (m), 1486 (s), 1439 (m), 1395 (s), 1339 (w), 1325
(m), 1305 (s), 1287 (s), 1249 (s), 1205 (s), 1180 (m), 1149
(w), 1092 (s), 1051 (m), 1033 (m), 995 (s), 973 (m), 949 (s),
926 (s), 873 (s), 854 (m), 830 (m), 817 (s), 805 (s), 794 (m),
782 (m), 744 (s), 716 (w), 676 (s), 665 (s) cm−1, 1H-NMR
(400.23 MHz, (CD3)2OS, 303 k): δ = 2.38 (s, 3H, OCH
3),
5.61(s, 1H, C12), 6.20-7.87 (m, H-aromatic), 9.76 (s, 1H, -
OH), 13C{1H}-NMR (150.9 MHz, (CD3)2OS, 303 k),
δ = 55.72 (CH3, OCH3), 103.98 (CH, C12), 111.65-147.21
(C & CH, C aromatic), 152.23 (C4,C18), 164.77 (C2,C14)
ppm, Elemental Analysis (C26H18O8), Calc. C: 68.12%, H:





IR analysis: 3400 (bd), 3070 (w), 1714 (s), 1605 (s), 1588
(s), 1561 (s), 1487 (s), 1453 (m), 1389 (m), 1342 (s), 1311
(w), 1275 (s), 1240 (m), 1212 (s), 1171 (m), 1106 (w), 1037
(s), 956 (s), 939 (s), 919 (m), 862 (m), 809 (s), 743 (s), 674
(m) cm−1, 1H-NMR (400.23 MHz, DMSO-d6, 303 k): δ =
5.78 (s, 1H, C12), 7.51-10.79(m, H-aromatic), 12.56(s, 1H,
-OH), 13C{1H}-NMR (150.9 MHz, DMSO-d6, 303 k): δ =
98.23 (CH, C12), 112-139 (C & CH, C aromatic), 158(C,
C14a), 161(C, Ar-OH), 181(C2,C14), ppm. Elemental Ana-
lysis (C25H18O7), Calc. C: 69.76%, H: 4.22%, Exp. C:
69.88%, H: 4.60%, EI-MS: m/z (%) 427.0818 (10%)
[C25H15O7-H
+], 265.0429 (80%) [C26H10O4]
+.
3.7 Synthesis of 3-(2-hydroxybenzoyl)-2H-chromen-2-
one (11) and 3-(2-hydroxybenzoyl)-2H-benzo[g]chromen-
2-one (12)
A mixture of 4.86 g (0.03 mol) 4-hydroxy-2H-chromen-
2-one and corresponding weights required for each alde-
hydes for 0.02 mol were mixed in 25 ml distilled and
dried ethanol. This mixture was refluxed for 2-3 hrs de-
pending upon the formation of solid products for each
aldehyde. After the formation of solid yellow products for
both 11 and 12, it was filtered and washed three times
with 2:1 mixture of methanol containing water and then
with n-hexane. 11 was recrystallized from methanol by
keeping the solution at room temperature for 24 hr.3.7.1 3-(2-hydroxybenzoyl)-2H-chromen-2-one (11)
IR analysis: 3400(bd), 3070(w), 1714(s), 1605(s), 1588(s),
1561(s), 1487(s), 1453(m), 1389(m), 1342(s), 1311(w),
1275(s), 1240(m), 1212(s), 1171(m), 1106(w), 1037(s),
956(s), 939(s), 919(m), 862(m), 809(s), 743(s), 674(m)
cm-1, 1H-NMR (400.23 MHz, DMSO-d6, 303 k): δ = 7.51
(t, 1H, H8a), 7.66(d, 1H, H7a), 7.76 (m, 1H, H6a), 7.83(d,
1H, H16a), 8.11(d, 1H, H17a), 8.31(d, 1H, H5a), 8.64(d,
1H, H15), 9.11(s, 1H, H18), 10.79(s, 1H, H10), 12.56(s,
1H, -OH), 13C{1H}-NMR (150.9 MHz, DMSO-d6, 303 k):
δ = 192(C, C12a), 181(C, C2), 165 (CH, C10a), 161
(CH, C18a) 158(C, C14a), 153(C, C4a), 139(CH, C15a),
135(CH, C5a), 132(CH, C17a), 131(C, C13a), 126(C,
C11a), 122(CH, C16a), 119(CH, C8a), 116(CH, C6a)
112(C, C9a), 91(CH, C7a) ppm, Elemental analysis: Exp.
C: 72.23%, H: 3.67%, Calc. C: 72.18%, H: 3.79%, Mass
spectra M+(%): 289.0473 (100%)[C16H10O4+Na]+.
3.7.2 2-(2-hydroxybenzoyl)-3H-benzo[f]chromen-3-one (2)
IR analysis: 3063(m), 1703(s), 1622(m), 1599(m), 1567(s),
1512(m), 1486(s), 1439(m), 1395(s), 1339(w), 1325(m), 1305
(s), 1287(s), 1249(s), 1205(s), 1180(m), 1149(w), 1092(s),
1051(m), 1033(m), 995(s), 973(m), 949(s), 926(s), 873(s),
854(m), 830(m), 817(s), 805(s), 794(m), 782(m), 744(s), 716
(w), 676(s), 665(s) cm-1, 1H-NMR (400.23 MHz, DMSO-d6,
303 k): δ = 5.60(s, 1H, H4), 6.94 (m, 1H, H11 & H12), 7.36
(m, 1H, H13), 7.51 (m, 1H, H10), 7.65 (d, 1H, H8), 7.76
(d, 1H, H7), 7.83 (d, 1H, H21), 8.10 (d, 1H, H22), 8.31
(d, 1H, H23), 8.64 (d, 1H, H20), 10.70 (s, 1H, H2) ppm, 13C
{1H}-NMR (150.9 MHz, DMSO-d6, 303 k): δ = 192(C,
C16), 181 (C, C2), 165.7 (CH, C10), 161.8 (CH, C23), 161.5
(C, C19), 159 (C, C6), 158 (CH, C4), 138.8 (CH, C13), 135
(CH, C20), 134.7 (C, C5), 132.7 (C, C9), 131 (CH, C22),
129.9 (CH, C21), 128.8 (CH, C8), 127.8 (CH, C7), 126 (C,
C3), 123.8 (CH, C11), 123 (CH, C12) ppm, Elemental ana-
lysis: Exp. C: 75.28%, H: 3.41%, Calc. C: 75.94%, H: 3.82%,
EI-MS+ (%): 339.0633 (70%) [C20H12O4+ Na]+.
Conclusion
Derivatizatin of 4-hydroxy coumarin have been carried
out with different aldehydes. The compounds were char-
acterized by various spectro-analytical techniques and it
was confirmed that mixtures of dicoumarol and trans-
lactonized products were obtained for compounds 5 and
10, compounds 1, 3 and 8 bear dicoumarol and com-
pound 2, 4, 6 and 7 exhibited dichromone structures.
Apart from it 11 was recrystallized and studied for single
crystal diffraction. The compound show Pca21 space
group and is connected by intermolecular hydrogen
bonding in the crystal lattice. The in vitro cytotoxic
screening of all the compounds and antimicrobial activ-
ities against different pathogenic microorganisms were
carried out. The compounds 1, 5, 7 and 10 were more
active against microbes than the standard drug used. In
Rehman et al. Chemistry Central Journal 2013, 7:68 Page 11 of 12
http://journal.chemistrycentral.com/content/7/1/68case of anticancer studies, the compound 10 and 11 have
been found most active against U2OS cancerous cells than
the previously reported tumorcidal drugs. Therefore the
effectiveness of these compounds can be utilized to design
significant anticancer agents.
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